Search

Your search keyword '"Jesus F"' showing total 763 results

Search Constraints

Start Over You searched for: Author "Jesus F" Remove constraint Author: "Jesus F" Database Unpaywall Remove constraint Database: Unpaywall
763 results on '"Jesus F"'

Search Results

4. Round Table Discussion on Optimal Clinical Trial Design in Precursor Multiple Myeloma

6. Predictors of unsustained measurable residual disease negativity in transplant-eligible patients with multiple myeloma

7. Profiling the dysregulated immune response in sepsis: overcoming challenges to achieve the goal of precision medicine

24. Widespread human exposure to ledanteviruses in Uganda - a population study

28. P848: EXPRESSION PROFILE OF BCL-2 FAMILY PROTEINS IN MULTIPLE MYELOMA.

29. Time-dependent prognostic value of serological and measurable residual disease assessments after idecabtagene vicleucel

35. Small babies, big risks: global estimates of prevalence and mortality for vulnerable newborns to accelerate change and improve counting

36. Emerging viruses are an underestimated cause of undiagnosed febrile illness in Uganda

37. Data from Perspectives on the Risk-Stratified Treatment of Multiple Myeloma

38. Supplementary Table from Perspectives on the Risk-Stratified Treatment of Multiple Myeloma

39. Supplementary Table from Perspectives on the Risk-Stratified Treatment of Multiple Myeloma

40. Data from Perspectives on the Risk-Stratified Treatment of Multiple Myeloma

41. Supplementary Table from Perspectives on the Risk-Stratified Treatment of Multiple Myeloma

42. Supplementary Table from Perspectives on the Risk-Stratified Treatment of Multiple Myeloma

43. Supplementary Data all from CCL2 Is a Vascular Permeability Factor Inducing CCR2-Dependent Endothelial Retraction during Lung Metastasis

44. Supplementary Data all from CCL2 Is a Vascular Permeability Factor Inducing CCR2-Dependent Endothelial Retraction during Lung Metastasis

47. Supplementary Figure from Circulating Tumor and Immune Cells for Minimally Invasive Risk Stratification of Smoldering Multiple Myeloma

48. Supplementary Table from Circulating Tumor and Immune Cells for Minimally Invasive Risk Stratification of Smoldering Multiple Myeloma

49. Supplementary Data from Circulating Tumor and Immune Cells for Minimally Invasive Risk Stratification of Smoldering Multiple Myeloma

50. Supplementary Table from Circulating Tumor and Immune Cells for Minimally Invasive Risk Stratification of Smoldering Multiple Myeloma

Catalog

Books, media, physical & digital resources